Articles tagged with Multiple Sclerosis
Researchers at Case Western Reserve University are studying a new approach to treat multiple sclerosis, focusing on toxic astrocytes that contribute to nerve-cell damage. They aim to develop medicines that prevent the formation of these cells and promote brain repair.
Silvana Lopes Costa, PhD, of Kessler Foundation has received the Women in Neurodegenerative Disease Rehabilitation Science Award for her groundbreaking research on multiple sclerosis and cognitive assessment. Her work aims to improve quality of life among individuals with neurological conditions through innovative rehabilitation science.
A new study suggests that a keto diet rich in ketone bodies may help alleviate symptoms of multiple sclerosis and other autoimmune disorders. The diet promotes the production of indole lactic acid, which blocks the activation of immune cells responsible for these conditions.
Scientists discovered that fragments of immune-stimulating proteins, called guardian peptides, are produced by the brain and spinal cord to maintain a healthy balance between defending against injury and infection and guarding healthy tissue. These peptides activate regulatory T cells to dampen abnormal immune reactions.
Researchers have unveiled a complex interplay between liver X and thyroid hormone receptors that regulates critical brain functions and protects against neurodegeneration. LXRs play a crucial role in regulating thyroid hormone function in the brain, while both receptors are essential for normal brain development and maintenance.
Scientists have discovered a natural compound called sulfuretin that can halt the progression of certain forms of cancer and demyelinating conditions like multiple sclerosis. The study found that sulfuretin blocks the activity of an enzyme involved in these diseases, suggesting its potential as a treatment.
Researchers have identified specific human endogenous retrovirus sequences associated with increased risk of neurodegenerative diseases, including multiple sclerosis and amyotrophic lateral sclerosis. The study suggests that these viral elements contribute to disease susceptibility by influencing brain function.
Scientists have identified a key driver of brain inflammation in neurological diseases, proposing a new treatment approach by neutralizing fibrin. This protein, involved in blood coagulation, triggers neurologic diseases by hijacking the immune system, resulting in damaged neurons.
A University of Michigan-led study found that treatment with either modafinil or cognitive behavioral therapy alone was associated with significant reductions in fatigue over 12 weeks. A combination of both treatments worked as well as each individual treatment but did not result in better fatigue scores.
A new study found an association between some types of cancer and multiple sclerosis (MS), with people with MS having a 6% increased risk of developing any type of cancer. The study identified higher risks for bladder, brain, and cervical cancers, but lower risks for prostate, colorectal, and breast cancers.
A study of identical twins found that CD8-positive T cells play a key role in the early stages of multiple sclerosis. The researchers discovered that these cells exhibit increased migration ability, promote inflammation and show activation markers, suggesting they are already embarking on their journey to the central nervous system. Th...
A new study explores a promising combined therapy for multiple sclerosis, using tolerogenic dendritic cells modified with myelin antigens. Researchers found that these cells from patients have a persistent pro-inflammatory signature, making them less effective compared to those derived from healthy individuals.
Researchers developed a new combined therapy for multiple sclerosis, combining tolerogenic dendritic cells with Dimethyl Fumarate to restore immune balance. The treatment showed promise in preclinical studies, reducing symptoms in mice and potentially offering hope for patients worldwide.
A new study found that people taking certain medications for primary progressive multiple sclerosis (MS) do not experience a slower rate of disability progression compared to those not receiving treatment. The study, published in Neurology, suggests that anti-CD20 therapies may not be effective in slowing disability progression.
A pioneering study identified critical biomarkers that can predict disability worsening in MS. Elevated serum neurofilament light chain and serum glial fibrillary acidic protein levels correlate with progression independent of relapse activity, guiding personalized treatment approaches.
A study by Amber Salter found that people with multiple sclerosis (MS) who have comorbidities experience worsened disease activity. The research highlights the importance of addressing comorbidities in MS treatment.
A recent study found significant therapeutic inertia in the treatment of women with multiple sclerosis (MS), leading to delayed or reduced use of disease-modifying treatments. The research highlights gender disparities that could impact long-term health outcomes for women of childbearing age, particularly due to concerns about pregnanc...
Researchers at the Plasticity and Remodeling of Neural Circuits laboratory aim to stimulate myelin plasticity to regenerate affected nerve fibers in MS patients. The team will explore gene therapy, pharmacological approaches, and rehabilitation strategies to enhance myelin repair.
A new study presented at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood can lead to improved long-term outcomes for children with MS. The research showed a substantially lower risk of progressing to higher disability levels in the early treatment group, particularly in moderate disability range.
A landmark study has identified novel ancestry-specific genetic variants linked to multiple sclerosis (MS) risk, offering new insights for treatment approaches. The research highlights the potential of ancestry-informed genetic studies to uncover previously unidentified risk factors for MS.
A new study published in The FEBS Journal found that protein C1QL1 plays a crucial role in promoting the replacement of specialized cells responsible for producing myelin. This discovery could lead to novel therapies for demyelinating diseases like multiple sclerosis.
Researchers at Kessler Foundation develop a new clinical protocol to improve learning and memory in individuals with multiple sclerosis who have mobility disability. The study combines aerobic exercise with virtual reality and cognitive rehabilitation, showing potential synergistic effects on cognitive improvements.
Researchers have created the largest collection of patient stem cell models of multiple sclerosis, identifying unique ways in which glia contribute to the disease. The study suggests that glial cells from MS patients have intrinsic hallmarks of disease, independent of immune system influences.
A new study from Washington University School of Medicine found that people with multiple sclerosis are less likely to develop the molecular hallmarks of Alzheimer's disease. The discovery suggests a potential new avenue for treating Alzheimer's and could inform therapeutic strategies.
A new study published in Neurology found that COVID-19 vaccination does not increase the risk of relapse in people with multiple sclerosis. However, participants with high MS activity and those who received booster doses did show a small increased risk, especially if they were not taking disease-modifying treatments.
A Wayne State University research team led by Taylor Takla is studying the neural, motor, cognitive and psychological factors underlying fear of falling in multiple sclerosis patients. The goal is to break the cycle of falls, reduced physical activity and social isolation, ultimately improving quality of life for MS patients.
Fatigue affects up to 90% of individuals with MS, significantly impacting their daily lives. The study proposes that disruptions in the cortico-striato-thalamo-cortical loop contribute to central fatigue.
Researchers have developed a new therapy called PIPE-307 that targets an elusive receptor on certain cells in the brain, prompting them to mature into myelin-producing oligodendrocytes. This could potentially reverse damage caused by multiple sclerosis, leading to improved movement, balance, and vision.
A recent study published in Scientific Reports found that blocking connexin 43 (Cx43) channels with the compound INI-0602 improved MS symptoms in an animal model by regulating immune processes and reducing inflammation. The findings suggest a potential therapeutic strategy for chronic MS treatment.
A new study published in PLOS Digital Health found that machine learning models can reliably predict the disability progression of multiple sclerosis. The models were trained on data from 15,240 adults with at least three years of MS history and had an average accuracy of 0.71 ± 0.01.
Researchers study T cells and monocytes interaction in the meninges before they attack the brain and spinal cord, potentially leading to new disease progression targets. The findings could provide a pathway to treating other neurological diseases like Alzheimer's and Parkinson's.
Researchers at Durham University have developed a groundbreaking method to diagnose Multiple Sclerosis using advanced eye imaging techniques. The innovative approach integrates optical coherence tomography and infrared scanning laser ophthalmoscopy, achieving an impressive 92% accuracy in initial tests.
A new study published in Neurology found that ofatumumab is more effective than teriflunomide at helping people with relapsing-remitting MS reach a period of no disease activity across racial and ethnic groups. The medication showed consistent results among diverse populations, including Black, Hispanic, and Asian individuals.
The WISDOM project aims to integrate healthcare and research data to combat CIMDs through AI-driven models. The initiative hopes to improve disease diagnosis, treatment, and patient outcomes by sharing data securely across borders.
Researchers have discovered several rare types of helper T cells associated with immune disorders such as multiple sclerosis and rheumatoid arthritis. The study found that genetic variants in bidirectional enhancer DNA are linked to specific immune-mediated diseases, including inflammatory bowel disease.
A pilot study found that remote cognitive rehabilitation using TELE-Self-GEN improved memory performance and daily life functionality in individuals with MS. The virtual intervention demonstrated high levels of participant satisfaction and effectiveness.
A pilot study found that methylphenidate enhances oculomotor function in individuals with multiple sclerosis, improving visual processing speed. The treatment also showed promise for mitigating cognitive symptoms associated with MS.
A new methodology, backward walking speed reserve, measures an individual's capacity to increase their walking speed on demand in the backward direction. This assessment is linked to disease severity, falls risk, and cognitive decline in multiple sclerosis patients.
Researchers at University of Cambridge uncover unified healer army of regulatory T cells that constantly move and repair damaged tissue. This discovery has implications for treating various diseases, including autoimmune disorders and infectious diseases.
Researchers investigate Epstein-Barr Virus and Multiple Sclerosis connection, discovering cross-reactivity between viral proteins and brain proteins. The study suggests that differences in immune cell function may explain why some people develop MS after EBV infection.
Researchers discovered how Epstein-Barr virus (EBV)-infected B cells contribute to multiple sclerosis (MS) inflammation and disease. A new treatment strategy targeting these problematic cells may offer a selectively cytotoxic approach to MS therapy.
Researchers found that abnormally active B cell metabolism causes an inflammatory immune response in individuals with Multiple Sclerosis (MS), leading to nerve damage and symptoms. Emerging BTK inhibitors alter this abnormal B cell respiration, stopping the signaling that leads to MS flare-ups.
FutureNeuro, a leading SFI Research Centre, is expanding its research programme with a focus on diagnostics, therapeutics, and digital health. The centre aims to develop precision diagnostics, future treatments, and systems using real-time health data.
A new study found extensive alternative splicing of messenger RNA in untreated multiple sclerosis patients compared to healthy controls. Interferon-ß therapy corrected dysregulated alternative splicing, linking it to future clinical exacerbations.
Researchers have discovered a small molecule compound called ESI1 that can regenerate vital myelin coatings, potentially treating multiple sclerosis and age-related cognitive deficits. The treatment promotes healing by clearing a roadblock in the repair process, allowing oligodendrocytes to produce myelin sheaths.
Alexander Gow is studying the disease's effects on oligodendrocytes to provide new insight into the development and origins of MS. He aims to develop improved treatments by identifying a protein called Trb3 that may be a good drug target for the disease.
A study published by the American Academy of Neurology found that immigrants to Canada who spend a greater proportion of their lives in the country have a higher risk of developing multiple sclerosis. The study involved 1.5 million immigrants and found that those who spent 70% of their lives in Canada were 38% more likely to develop MS.
Researchers found that older adults tend to conserve energy by modifying their movements under certain circumstances. The findings suggest that the effort costs of reaching are a determining factor in slowing movement with age. This research may lead to new tools for diagnosing diseases, including Parkinson's and multiple sclerosis.
A new study from Brigham and Women's Hospital suggests that PET brain scans can detect hidden inflammation in MS patients who are being treated with highly-effective treatments. The findings indicate that smoldering inflammation may linger in patients, driving disease progression and symptoms.
Researchers have identified CAR-T cell therapy as a potential treatment for autoimmune diseases such as rheumatoid arthritis, SLE, and type 1 Diabetes Mellitus. Early studies have shown promising results in reducing disease activity and improving patients' quality of life, but long-term data on safety and efficacy is limited.
Researchers identified a unique autoantibody signature in approximately 10% of patients with MS, appearing years before symptom onset. This finding could revolutionize patient care and treatment strategies for multiple sclerosis.
Scientists have identified a consistent signature of multiple sclerosis in the blood of patients years before they develop symptoms. The discovery, published in Nature Medicine, could lead to earlier diagnosis and treatment of the disease, affecting nearly 1 million people in the US.
Researchers used fitness trackers and smartphone data from 55 MS patients and 24 controls to identify clinically useful information. Data on physical activity, heart rate variability, and phone usage revealed relationships between disease severity, fatigue levels, and motor function.
A new study by Kessler Foundation scientist Glenn Wylie will independently investigate brain networks associated with 'state' fatigue in MS. The research aims to validate 'state' measures of fatigue and offer a more accurate assessment of primary fatigue, potentially improving the quality of life for individuals living with MS.
Researchers have identified three distinct immunological endophenotypes of multiple sclerosis, defined by specific blood immune signatures. These findings could lead to more effective and tailored treatment strategies for patients with the disease.
A team of researchers at Trinity College Dublin has developed a new blood test that measures the immune response to Epstein Barr Virus (EBV), which is the leading risk factor for multiple sclerosis (MS). The study found that people with MS have a higher immune response to EBNA-1, a part of the EBV, compared to those without MS.
Dr. Rhonda Voskuhl's groundbreaking research has shed light on the mechanisms underlying sex differences in MS, highlighting a gene on female sex chromosomes that promotes inflammation and brain-protective effects of estrogen. Her work may lead to new treatment approaches for MS.
A UK study found that individuals with multiple sclerosis had a seven times greater risk of hospitalization and a four-fold increased risk of dying from COVID-19, even after repeated doses of vaccines. Vaccination alone may not adequately protect this vulnerable population, highlighting the need for additional preventive measures.
A study found that children and adolescents with obesity are at a significantly higher risk of developing multiple sclerosis, with the risk being more than two-fold. The study also suggests that the persistent low-grade inflammatory state associated with obesity may be mediating this association.
Researchers discovered that mature oligodendrocytes, critical for brain function, can survive for up to 45 days after a fatal trauma, defying the classical programmed cell-death pathway. This finding opens new avenues for understanding and potentially preventing damage caused by aging and neurodegenerative diseases.